Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.57 |
| ▸ | NPY4R | P50391 | 6/20 | 0.57 |
| ▸ | NPY1R | P25929 | 5/20 | 0.57 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | PRKACB | P22694 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118086 | 1.00 | GHSR (0.57) | GHSRNPY4RNPY1RNPY2RPRKACB | |
| SCHEMBL29641180 | 0.99 | GHSR (0.58) | GHSRNPY4RNPY1RNPY2RPRKACB | |
| SCHEMBL29641082 | 0.97 | GHSR (0.61) | GHSRNPY4RNPY1RNPY2RPRKACB | |
| SCHEMBL29641066 | 0.97 | GHSR (0.61) | GHSRNPY4RNPY1RNPY2RPRKACB | |
| SCHEMBL30169478 | 0.95 | GHSR (0.65) | GHSRNPY4RNPY1RNPY2RUTS2R | |
| SCHEMBL29641169 | 0.95 | GHSR (0.65) | GHSRNPY4RNPY1RNPY2RUTS2R | |
| SCHEMBL29641033 | 0.95 | GHSR (0.65) | GHSRNPY4RNPY1RNPY2RUTS2R | |
| SCHEMBL29641067 | 0.95 | GHSR (0.65) | GHSRNPY4RNPY1RNPY2RUTS2R | |
| SCHEMBL31193767 | 0.95 | NPY4R (0.60) | GHSRNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29576199 | 0.94 | GHSR (0.54) | GHSRNPY4RNPY1RNPY2RPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | GHSR 4526/4885NPY4R 3458/4885NPY1R 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.